Effect of Microbiome Modulation by Diet in Functional Constipation

Overview

Current medications and behavioral modifications have limited success in the treatment of functional constipation (FC). An individualized diet based on microbiome analysis may improve symptoms in FC. In the present study, we aimed to investigate the impacts of microbiome modulation on chronic constipation. patients fulfilling Rome IV criteria for functional constipation were randomized into two groups. The Control group received sodium picosulfate plus conventional treatments (i.e., laxatives, enemas, increased fiber, and fluid intake). The study group underwent microbiome analysis and received an individualized diet with the assistance of a soft computing system (Enbiosis Biotechnology®, Sariyer, Istanbul). Differences in Patient Assessment Constipation-Quality of Life (PAC-QoL) score and complete bowel movements per week (CBMpW) were compared between groups after 6 week-intervention.

Full Title of Study: “Effect of Artificial Intelligence-assisted Personalized Microbiome Modulation by Diet in Functional Constipation: a Randomized Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: December 27, 2021

Interventions

  • Other: Artificial intelligence-assisted personalized diet
    • The AI-based nutritional recommendations system is based on the eating rates of the individual in a certain period, to ensure the homeostasis of the microbiome and increase the microbial diversity. After the microbiome analysis reports of the study group are released, a 6-week diet was designed regarding AI-based food scores specific to constipated individuals in accordance with the individual’s lifestyle and comorbidities. Diet lists are updated according to the individual’s feedback, recovery level, and wishes with weekly meetings.

Arms, Groups and Cohorts

  • No Intervention: Control group
    • After randomization control group was recommended to continue their regular diet with increased fluid (2 lt/day) and fiber intake (30 g/day) and received 5 mg of sodium picosulfate daily for 10 weeks.
  • Experimental: Treatment group
    • In the study group, after fecal samples were taken, patients were recommended to continue their regular diet with increased fluid (2 lt/day) and fiber intake (30 g/day) for 4 weeks until the microbiome analysis resulted. During subsequent 6 weeks, they received the personalized microbiome modulatory diet.

Clinical Trial Outcome Measures

Primary Measures

  • Three or more complete bowel movements per week at 10 weeks
    • Time Frame: 10 weeks
    • The proportion of patients with a mean of three or more complete bowel movements per week (CBMpW) at 10 weeks is compared between control and study groups.
  • Improvement in Patient Assessment Constipation Quality of Life
    • Time Frame: 10 weeks
    • The proportion of the patients with more than 50% improvement in total Patient Assessment Constipation Quality of Life score is compared between control and study groups.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients fulfilling Rome IV criteria for functional constipation (FC) – Patients who had a colonoscopy performed within the last 5 years – Patients who had a colonic transit time assessment within the last 3 months – Patients who had a magnetic resonance defecography within the last 3 months Exclusion Criteria:

  • Use of antibiotics, probiotics, and/or prebiotics within the last 4 weeks – Gastrointestinal endoscopy within the last 4 weeks – Major gastrointestinal surgery (total/segmental gastrectomy, small bowel and/or colonic resection) – Cholecystectomy – Inflammatory bowel diseases – Celiac disease – Any etiology of chronic constipation other than FC (irritable bowel syndrome, rectocele, dyssynergic defecation, opioid use) – Endocrine, metabolic or neurologic disorders causing constipation (hypothyroidism, Parkinson's disease, paraplegia)

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Istanbul Medipol University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.